To bolster the increased demand for mRNA therapies, Germany’s Evonik Industries, in partnership with the U.S. government, is investing more than $200 million to build a lipid manufacturing facility in the United States.
https://www.pharmalive.com/wp-content/uploads/2022/06/BioSpaceEvonik6-2-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-02 11:56:552022-06-02 11:58:58Evonik to build $220 million lipid plant in U.S. for mRNA-based therapies